Influenza vaccine effectiveness against influenza A during the delayed 2022/23 epidemic in Shihezi, China

After the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza vir...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2023-09, Vol.41 (39), p.5683-5686
Main Authors: Su, Yinxia, Guo, Zihao, Gu, Xiu, Sun, Shengzhi, Wang, Kai, Xie, Songsong, Zhao, Shi
Format: Article
Language:English
Subjects:
Age groups
Body mass index
Consent
COVID-19
COVID-19 vaccines
Disease transmission
Effectiveness
Epidemics
Estimates
Illnesses
Infections
Influenza
Influenza A
Pandemics
Patients
Population
Public health
Sample size
Seasons
Vaccine efficacy
Vaccines
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:After the temporary end of COVID-19 in China in February 2023, the influenza epidemic peaked in March across many Chinese places. We recruited a total of 258 all-age subjects presenting influenza-like illness (ILI) in Shihezi city, China from January 1 to March 16, 2023, and tested for influenza virus infection. Using a test-negative design, we assessed influenza vaccine effectiveness (VE) of 56.3% (95% CrI: 13.6, 73.6) against medically attended, influenza illness during the delayed 2022/23 influenza epidemic. The findings contributed to the continuous monitoring of the influenza vaccine performance across the world, especially in the “post-COVID” pandemic era.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2023.08.039